Cybin to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

TORONTO–(BUSINESS WIRE)–Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce that Doug Drysdale, Cybin’s Chief Executive Officer, will participate in a fireside chat at the Lytham Partners 2025 Investor Healthcare Summit taking place virtually on January 13, 2025. The fireside chat
Read More

Researchers identify risk factors for poor prognosis in alopecia areata

Alopecia areata (AA) is a common autoimmune disease that leads to sudden circular hair loss. The clinical course of AA is unpredictable and varies greatly from individual to individual. Numerous studies have shown that AA is often associated with comorbid, i.e. co-existing, chronic inflammatory diseases, which can have an impact on prognosis and clinical management.
Read More

Humana Inc. to Release Fourth Quarter 2024 Results on February 11, 2025

LOUISVILLE, Ky.–(BUSINESS WIRE)–Humana Inc. (NYSE: HUM) will release its financial results for the fourth quarter 2024 (4Q24), as well as prepared management remarks (in PDF format), on Tuesday, February 11, 2025, at 6:30 a.m. Eastern time. The company will host a live question and answer session at 9:00 a.m. Eastern time that morning to discuss its financial results for the quarter and earnings guidance for 2025. To participate via telephone, please register in advance using this link, https
Read More
Top